



Name **Hirohito Yamaguchi**
Current Positions Professor, Graduate Institute of Biomedical Sciences,
China Medical University

Telephone +886-4-22053366, ext. 6736
E-mail hyamaguchi@mail.cmu.edu.tw; hirohitoyamaguchi@yahoo.com
E-Portfolio Website https://webap.cmu.edu.tw/TchEportfolio/index_1/hyamaguchi
Personal Website

Education

BS, DVM, University of Tokyo, Tokyo, Japan (1996)
PhD in Veterinary Medical Sciences, University of Tokyo, Tokyo, Japan (2000)
Postdoc in Cancer Biology, H. Lee Moffitt Cancer Center, Florida, USA (2000 ~ 2004)

Expertise

Cancer biology, Drug resistance, Signal transduction, Cell death

Research Interests

My research interests include the regulation of cell proliferation, death, and survival of human cancer that is essential for cancer progression and drug resistance. When cancer patients are being treated with anti-cancer drugs, cancer cells are exposed to even higher levels of stresses. However, cancer cells frequently become resistant to these stresses and continue to grow, which eventually lead to mortality. Thus, evading cell death/cell cycle arrest is one of the most important hallmarks of cancer, and an obstacle for successful cancer treatment. One of my long-term research goals is to dissect signaling pathways critical for the stress response of cancer cells, which would lead to novel effective strategies to target this disease.

Selected Grants:

PI: CMU start-up fund (2021/3-current)

Selected Publications

1. Saab S, Chang OS, Nagaoka K, Hung MC, Yamaguchi H*. The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors. *American Journal of Cancer Research*. 9(12):2719-2729. 2019, IF=6.166
2. Dong Q, Du Y, Li H, Liu C, Wei Y, Chen MK, Zhao X, Chu YY, Qiu Y, Qin L, Yamaguchi H*, Hung MC*. EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma. *Cancer Research*. 79(4):819-829. 2019, IF= 12.071

Selected Patents

1. N/A